WhatsApp used in research, but is this ethical?

By HEOR Staff Writer

March 15, 2023

Globally, WhatsApp Messenger has emerged as one of the world’s fastest-growing MIM applications. It has particularly high penetration rates in India, Indonesia, Malaysia, Brazil and South Africa.

The sub-Saharan African region is characterized by mixed migration flows and multiple health challenges, due to the inequalities experienced in access to healthcare disproportionately affect many groups including migrants and mobile populations. Given the existing structural factors impeding access to healthcare, coupled with high rates of mobile telephone use across the sub-Saharan African region; mobile phones are consistently recognized as having great potential for improving access to healthcare in this context.

WhatsApp was largely used in one of two ways for health research; to send hyperlinks to online surveys, or to deliver and evaluate, either an intervention designed for healthcare users or a communication programme for healthcare providers.

Challenges include efforts taken to ensure privacy, confidentiality and anonymity when using WhatsApp as a data collection tool; significant gender divide in access to mobile phones, with men being far more likely to have access to a device than women; features in WhatsApp that could potentially allow some encrypted messages to be read by unintended recipients, compounding the possible breaches of WhatsApp data.

Reference url

Recent Posts

Health Investment Returns: Harnessing Health as a Strategic Economic Asset

By João L. Carapinha

November 18, 2025

Health as a Strategic Economic Imperative A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recent EFPIA Guest Blog by Michael Oberreiter frames he...
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gram-Negative Infections
Emblaveo Approved for MDR Gram-Negative Infections Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avibactam) for financing under Decree-Law No. 97/2015....
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost Treatments

By João L. Carapinha

November 14, 2025

Evolving Landscape of Targeted Therapies and Access Challenges Expanding targeted therapy access remains a critical challenge amid the pharmaceutical market's shift toward high-cost innovations, such as orphan drugs and...